drugset / Trial / NCT00539591
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Phase 2
Active not recruiting
29 enrolled
St. Jude Children's Research Hospital
Schering-Plough · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous melanoma.
Timeline
- Start
- 2008-05-09
- Primary completion
- 2015-06
- Completion
- 2031-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 0.5 ug/kg | Intravenous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 1 ug/kg | Intravenous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 2e+07 unknown | Intravenous |
| Subject | Temozolomide | Small molecule | 75 mg/m2 | Oral |